Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

doi:10.5306/wjco.v15.i6.717

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1847)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

138

HTML

1315

Figures (1-1)

118

Tables (1-1)

112

Sum=1683

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=101

Jun 24, 2024 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Jun 24, 2024; 15(6): 717-729
Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.717

Full Size Figure Download Figure

Figure 1 Schematic representation of the interplay among dyslipidemia, atherosclerosis, and myeloproliferative neoplasms, with a focus on the main pathogenetic mechanisms that drive the development of atherosclerosis. CHIP: Clonal hematopoiesis of indeterminate potential; HSC: Hematopoietic stem cells; MPNs: Myeloproliferative neoplasms.

Citation: Găman MA, Srichawla BS, Chen YF, Roy P, Dhali A, Nahian A, Manan MR, Kipkorir V, Suteja RC, Simhachalam Kutikuppala LV, Găman AM, Diaconu CC. Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms. World J Clin Oncol 2024; 15(6): 717-729
URL: https://www.wjgnet.com/2218-4333/full/v15/i6/717.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i6.717